News
12 Health Care Stocks Moving In Monday's Intraday Session
6 May 24
Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
1 May 24
Movers
12 Health Care Stocks Moving In Tuesday's After-Market Session
30 Apr 24
Movers
Gold Down Over 2%; 3M Profit Beats Expectations
30 Apr 24
Earnings, News, Eurozone, Commodities, Intraday Update, Markets, Trading Ideas
Why H&E Equipment Services Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
30 Apr 24
News, Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Tuesday's Intraday Session
30 Apr 24
Movers
Nasdaq Down 0.5%; Lithium Americas Shares Slide
18 Apr 24
News, Commodities, Intraday Update, Markets, Movers
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Apr 24
Movers
Crude Oil Edges Lower; Bio-Path Holdings Shares Spike Higher
18 Apr 24
Earnings, News, Intraday Update, Markets, Movers
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
18 Apr 24
Earnings, News, Markets, Movers
Dow Surges Over 100 Points; D.R. Horton Posts Upbeat Earnings
18 Apr 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
NRx Pharmaceuticals Receives Notice From Nasdaq That The Company Has Demonstrated Compliance With The Bid Price Requirement
18 Apr 24
News
NRx Pharmaceuticals, Inc. Announces Pricing Of $2M Underwritten Public Offering Of Common Stock At A Public Offering Price Of $3.30 Per Share
18 Apr 24
News, Offerings
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24
Movers
Why Alcoa Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
18 Apr 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
NRx Pharmaceuticals Intends To Offer To Sell Shares Of Its Common Stock In Public Offering; No Terms Disclosed
17 Apr 24
News, Offerings
(NRXP) - Analyzing NRX Pharmaceuticals's Short Interest
15 Apr 24
Short Sellers, Short Ideas, Trading Ideas
NRx Pharmaceuticals Announces Development Of New, Proprietary Formulation Of HTX-100 (IV Ketamine)
15 Apr 24
Biotech, News, General
NRx Pharmaceuticals Announces Data-Lock Of Phase 2b/3 Trial Of NRX-101 In Suicidal Treatment Resistant Bipolar Depression; With Data From This Study And FDA Comment, NRx Becomes Eligible To Receive The Balance Of Its First Milestone Of An Additional $4M From Partners Alvogen, Inc. And Lotus Pharmaceuticals, Inc.
8 Apr 24
Biotech, News, General
NRX Pharmaceuticals Q4 EPS $(0.05) Beats $(0.07) Estimate
28 Mar 24
Earnings, Earnings Beats, News
Press releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Participate in the EF Hutton Annual Global Conference on May 15, 2024
8 May 24
Press Releases
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Report First Quarter 2024 Financial Results on May 14, 2024
7 May 24
Press Releases
Final Clinical Trial Results Show Superior Safety and Efficacy for NRX-101; Plans to Seek Accelerated Approval for Bipolar Depression and Schizophrenia: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)
6 May 24
News, Press Releases
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Final Clinical Trial Results: Superior Safety Combined with Similar Efficacy in the Trial of NRX-101 Compared to Lurasidone in Suicidal Bipolar Depression
6 May 24
Press Releases
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
30 Apr 24
Press Releases
NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
18 Apr 24
Press Releases
NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
18 Apr 24
Offerings, Press Releases
NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
17 Apr 24
Offerings, Press Releases
New Data on Infection Avoidance and Development of pH Neutral Ketamine, for Intravenous and Subcutaneous Use: NRx Pharmaceuticals (Nasdaq: NRXP)
17 Apr 24
News, Press Releases
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
17 Apr 24
Press Releases
Successful Development of pH Neutral Ketamine, Potentially Enabling Both Intravenous and Subcutaneous Use; Trials Progressing for Suicide Drug Treatment After Strong Q4 Results: NRXP
15 Apr 24
News, Press Releases
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
15 Apr 24
Press Releases
NRX's (NASDAQ: NRXP) NMDA Modification Therapy And Its Multiple Applications From Mental Health To Chronic Pain
11 Apr 24
Data Lock Achieved in Latest Clinical Trials for Suicidal Treatment After Strong Q4 Results with Approved Stock Dividend and Share Structure Reduction to Counter Short Selling: NRXP
8 Apr 24
News, Press Releases
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
8 Apr 24
Press Releases
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
28 Mar 24
Press Releases
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
28 Mar 24
Stock Split, Press Releases
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
26 Mar 24
Press Releases
Upcoming Stock Dividend Coupled with Approved Share Structure Reduction Intended to Counter Short Selling and Boost Institutional Investment, Key Company Presentation Coming Up in UK: NRXP
26 Mar 24
News, Press Releases
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
25 Mar 24
Press Releases